Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
AuthorsMarsh, E A
Hirst, C L
Llewelyn, J G
Cossburn, M D
Reilly, M M
Ryan, A M
Coles, A J
Jones, J L
Robertson, N P
AffiliationDepartment of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.
Age of Onset
Anemia, Hemolytic, Autoimmune
Antibodies, Monoclonal, Humanized
Drug Therapy, Combination
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
MetadataShow full item record
CitationAlemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. 2010, 257 (6):913-9 J. Neurol.
JournalJournal of neurology
AbstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.
- Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
- Authors: Tracy JA, Dyck PJ
- Issue date: 2010 Jun
- Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
- Authors: Seino Y, Nakamura T, Hirohata M, Kawarabayashi T, Okushima T, Shoji M
- Issue date: 2019 Mar 15
- Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
- Authors: Hirst C, Raasch S, Llewelyn G, Robertson N
- Issue date: 2006 Jun
- Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
- Authors: van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS, PATH study group.
- Issue date: 2016 Jul 25
- Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
- Authors: Broyles R, Rodden L, Riley P, Berger M
- Issue date: 2013 Mar